





9. A method of treatment according to claim 8 wherein the inflammatory disorder of the respiratory tract is asthma.
10. An inhaler containing a plurality of doses of a pharmaceutical formulation comprising a compound of formula (I)



or a solvate thereof, together with a long-acting  $\beta_2$ -adrenoreceptor agonist, which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more, and which doses are suitable for once-per-day administration of the formulation by inhalation.

11. An inhaler according to claim 10 wherein the compound of formula (I) or a solvate thereof and the long-acting  $\beta_2$ -adrenoreceptor agonist are both present in particulate form.
12. An inhaler according to claim 11 wherein the formulation further comprises a particulate carrier.
13. An inhaler according to claim 12 wherein the carrier is lactose.
14. An inhaler according to claim 10 wherein the formulation further comprises a liquefied propellant gas.
15. An inhaler according to claim 11 wherein the formulation further comprises a liquefied propellant gas.
16. An inhaler containing a plurality of doses of a pharmaceutical formulation comprising a particulate compound of formula (I)

58



or a solvate thereof, a particulate long-acting  $\beta_2$ -adrenoreceptor agonist and a carrier, each drug being present in an amount adequate to provide a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more following once-per-day dosing by inhalation.

17. An inhaler according to claim 10 wherein wherein the inflammatory disorder of the respiratory tract is asthma.
18. An inhaler according to claim 16 wherein wherein the inflammatory disorder of the respiratory tract is asthma.